Typhoid Vaccine Recalled

An estimated 700,000 people immunized against typhoid may not be fully protected.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Salmonella enterica (serovar typhimurium)Centers for Disease Control and PreventionThe typhoid vaccine called Typhim Vi made by Sanofi Pasteur was recalled this week (October 8), due to insufficient potency in 88 percent of its stock. Anyone immunized after January 2011 could have received the weaker vaccine that may not protect against infection, reported BBC News.

Typhoid fever, in which patients can experience sustained temperatures of 103 degrees Fahrenheit or higher, as well as stomach pains and rose-colored spots, is caused by the bacterium Salmonella Typhi. The disease is not common in the United Kingdom or the United States, but it still causes 21 million infections per year in the developing world. Visitors to South or South East Asia commonly get the vaccine prior to travel, and the U.K.’s Medicines and Healthcare products Regulatory Agency said that travelers returning from those areas should be vigilant for signs of disease, and contact a doctor immediately if symptoms appear.

"There are no concerns over the safety of this vaccine, but the recall has taken place because the vaccine may not be as effective ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo